Dr Lucas Chan
PhD / FRSB / CBioI
As a chartered biologist and fellow of the Royal Society of Biology, Dr Chan has more than 15 years of experience in the research and development of retroviral and lentiviral gene therapy vectors. He was part of the team that developed the first patented suspension culture packaging cell line2. During his stint as Head of Production for Advanced Therapies at King’s College London Clinical Research Facility, Dr Chan led the establishment of the first GMP-compliant viral vector manufacturing site in Europe.
During his tenure in London, Dr Chan oversaw the production of more than 30 batches of clinical-grade viral vectors in support of more than 20 first-in-man clinical trials. His experience with viral vectors also spans diverse therapeutic areas from rare diseases to novel CAR-T therapies.
Some notable clinical applications of viral vectors developed by Dr Chan:
Lentiviral vector CD80/IL-2 immune gene therapy for post-transplant Acute Myeloid Leukaemia in Cancer Immunol Immunother 2010;59:379–388.
Lentiviral vector GM-CSF/IL-4 derived SMART-DC, a dendritic cell cancer vaccine against TRP2+ melanoma in Gene Ther 2015;22:707-720.
Lentiviral vector SPINK5 for Netherton Syndrome in Hum Gene Ther Clin Dev 2013;24:182-190.
Retroviral vector CD34/HSV-TK for the control of GVHD in PLoS One 2013:21;8:e77106.
Retroviral vector HBsAg TCR against HBV+ HCC in J Hepatol 2015;62:486-491.
Lentiviral vector COL7A1 for Epidermolysis Bullosa in J Invest Dermatol 2016;136:2842-92
Lentiviral vector CAR19 for B Cell Malignancies in Sci Transl Med 2017;9:eeaj2013.
Dr Lim ZiYi
MBChB (Edin) / MRCP (UK) / FRCPath (UK)
A renowned haemato-oncologist, Dr Lim obtained his medical degree from the University of Edinburgh before undergoing his specialist training at King’s College Hospital, London. In the subsequent nine years, Dr Lim led the development of King’s College Hospital’s allogeneic haematopoietic stem cell transplant centre.
Dr Lim returned to Singapore in 2011 where he served as the clinical lead of the adult leukaemia service and the adult clinical cellular therapy service of the National University Cancer Institute. In recognition of Dr Lim’s efforts in bringing novel therapies from bench to bedside, he was conferred the NUHS Clinician Scientist Program Award in 2012.
With a wealth of experience in allogeneic haematopoietic stem cell transplantation – including umbilical cord blood and haploidentical transplantation – Dr Lim presently leads the Transplant Program at Parkway Cancer Centre, Singapore. He also oversees the research and development programme at Stem Med.